MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism

• Status: Completed
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to investigate if androgen deprivation therapy in men with prostate cancer increases hepatic fat content and changes visceral/subcutaneous fat distribution.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Herlev Hospital
• Treatments: Androgens; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• Eligible for inclusion are patients who are included in the already ongoing Randomised trial entitled: Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin (EudraCT number: 2013-002553-29)

Exclusion Criteria:

• Implanted devices or foreign metallic bodies incompatible with Magnetic Resonance Imaging.

• claustrophobia

• Severe Psychiatric disease